Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of pharmaceutical company Impax Laboratories (NASDAQ: IPXL ) dropped as much as 10% after the Food and Drug Administration sent the company a complete response letter, or CRL, for its idiopathic Parkinson's disease drug, Rytary.
So what: The CRL from the FDA was issued with regard to the supportive manufacturing and distribution aspect of Rytary, and it requested a re-inspection of the company's Hayward manufacturing facility. Impax, however, had removed Hayward from its list of supportive manufacturing facilities prior to its new drug application submission due to a warning letter from the FDA regarding manufacturing at the facility in 2011.
Now what: Impax's management is basically shrugging its shoulders at the moment because I don't think it has the slightest clue what the FDA is looking at with regard to Rytary's manufacturing process. It's going to take some very close hand-in-hand cooperation from both sides to resolve this, meaning it could be quite a while before Rytary gets resubmitted. Rytary's efficacy and safety don't seem to be the question here, so we're talking about a drug whose eventual approval appears very likely. This is one of the primary reasons Impax isn't tanking, and a reason why GlaxoSmithKline (NYSE: GSK ) , the owner of Rytary's rights outside the U.S., is hardly budging, either. But, it's still going to be about another six months to a year out before we get a verdict.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Craving more input? Start by adding Impax Laboratories to your free and personalized watchlist so you can keep up on the latest news with the company.